News
ANAB
19.83
-7.64%
-1.64
Leerink Partners Initiates Coverage of AnaptysBio (ANAB) with Outperform Recommendation
NASDAQ · 2d ago
AnaptysBio Price Target Announced at $47.00/Share by Leerink Partners
Dow Jones · 3d ago
AnaptysBio Initiated at Outperform by Leerink Partners
Dow Jones · 3d ago
Leerink Partners Initiates Coverage On AnaptysBio with Outperform Rating, Announces Price Target of $47
Benzinga · 3d ago
ANAPTYSBIO INC <ANAB.O>: LEERINK PARTNERS INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $47
Reuters · 3d ago
How The Parts Add Up: VBK Headed For $289
NASDAQ · 3d ago
U.S. RESEARCH ROUNDUP-Advanced Micro Devices, Kroger, Tyson Foods
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Advanced Micro Devices, Kroger and Tyson Foods among companies with new targets. Analysts raise ratings and target prices on several companies. Boeing, Caterpillar and AIG among those with targets raised.
Reuters · 3d ago
Weekly Report: what happened at ANAB last week (0408-0412)?
Weekly Report · 4d ago
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
AnaptysBio's shares closed the week almost 8% higher in price. A bullish new analyst take on the company helped it rally on the market. Wells Fargo initiated coverage of Anaptys bio with an overweight recommendation. The bank believes the biotech is sorely undervalued.
The Motley Fool · 6d ago
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Fastenal shares dipped 6.7% to $69.73 on Thursday. The company reported worse-than-expected first-quarter financial results. Rallybio Corporation shares climbed 89.6% after company announced a collaboration with Johnson & Johnson. Rent the Runway, Inc. Shares jumped 74.5% after the company reported mixed fourth-quarter results.
Benzinga · 04/11 17:33
Thursday's ETF Movers: XBI, KIE
NASDAQ · 04/11 16:42
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Enliven Therapeutics shares surged 26% to $24.97 on Thursday. The Dow Jones index fell over 50 points in today's session. Shares of Rallybio Corporation jumped 89.6% after the company announced a collaboration with Johnson & Johnson. U.S. Stocks were mixed on Thursday as Enliven shares rose sharply.
Benzinga · 04/11 14:01
AnaptysBio Initiated at Overweight by Wells Fargo
Dow Jones · 04/11 13:56
AnaptysBio Price Target Announced at $56.00/Share by Wells Fargo
Dow Jones · 04/11 13:56
Wells Fargo Initiates Coverage On AnaptysBio with Overweight Rating, Announces Price Target of $56
Benzinga · 04/11 13:45
ANAPTYSBIO INC <ANAB.O>: WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING ; TARGET PRICE $56
Reuters · 04/11 10:24
Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock.
NASDAQ · 04/09 18:40
Weekly Report: what happened at ANAB last week (0401-0405)?
Weekly Report · 04/08 09:17
Unveiling 4 Analyst Insights On AnaptysBio
AnaptysBio is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. 4 analysts have released ratings for Anaptys bio in the last three months. Analysts have set 12-month price targets for the company of $53.25 and $80.00.
Benzinga · 04/01 19:01
AnaptysBio Price Target Cut to $28.00/Share From $30.00 by JP Morgan
Dow Jones · 04/01 14:16
More
Webull provides a variety of real-time ANAB stock news. You can receive the latest news about Anaptysbio Inc through multiple platforms. This information may help you make smarter investment decisions.
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering immunology therapeutics. The Company is developing immune cell modulators, including two checkpoint agonists for autoimmune and inflammatory disease: rosnilimab, its PD-1 agonist, in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis; and ANB032, its BTLA agonist, in a Phase 2b trial for the treatment of atopic dermatitis. The Company's preclinical immune cell modulator portfolio includes ANB033, an anti-CD122 antagonist antibody, and ANB101, a BDCA2 modulator antibody, for the treatment of autoimmune and inflammatory diseases. In addition, it has developed two cytokine antagonists available for out-licensing: imsidolimab, an anti-IL-36R antagonist, in Phase 3 for the treatment of generalized pustular psoriasis, or GPP, and etokimab, an anti-IL-33 antagonist for the treatment of respiratory disorders that is Phase 2/3 ready.